Find, compare & contact
Insulin Aspart
API Manufacturers & Suppliers
Bangladesh
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Follow us
Produced in:
Established in: 2017
MOQ: -
Employees: 200+
Manufacturing facility approved by FDA and GMP certified
Obtained CNAS laboratory accreditation certificate
Subsidiary of the US listed group Amphastar Pharmaceuticals
+ 0
All certificates
Producer
Produced in:
Established in: 2019
MOQ: 1 g
Employees: 10+
Focused on pharmaceutical industry
Reasonable price for the customers
Full service from R&D stage to commercial stage
+ 0
All certificates
Producer
Produced in:
Established in: 1995
MOQ: -
Employees: 10000
Fermentation technology Experts
Partnerships with 1200 pharma companies in 100+ countries
US FDA, EMA, COFEPRIES, ANVISA, PMDA accreditations
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Insulin Aspart API 116094-23-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Insulin Aspart. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Insulin Aspart
- Synonyms:
- Aspart , Aspart Insulin , B28-Aspart-Insulin , INA-X14 , Insulin X14
- Cas Number:
- 116094-23-6
- DrugBank number:
- DB01306
- Unique Ingredient Identifier:
- D933668QVX
About Insulin Aspart
Here is a short description about Insulin aspart. Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.
Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin aspart, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D.
Ask the supplier for a certificate of analysis to find out more about the quality of Insulin aspart.
Insulin Aspart is a type of Insulin
Insulin is a vital pharmaceutical Active Pharmaceutical Ingredient (API) that plays a crucial role in managing diabetes. It is a hormone produced by the pancreas and is responsible for regulating blood sugar levels in the body. Insulin is used extensively in the treatment of diabetes, a chronic condition characterized by insufficient insulin production or impaired insulin action.
As an API, insulin is available in various forms, including human insulin and analog insulin. Human insulin is derived from recombinant DNA technology, where it is synthesized using genetically engineered bacteria or yeast. Analog insulin, on the other hand, is a modified version of human insulin that is designed to mimic the body's natural insulin action more closely.
Insulin APIs are utilized in the production of pharmaceutical formulations such as insulin injections, insulin pens, and insulin pumps. These formulations are essential for individuals with diabetes who require regular insulin administration to maintain proper blood sugar control.
The development and production of insulin APIs require stringent quality control measures to ensure their safety and efficacy. Manufacturing processes must adhere to Good Manufacturing Practices (GMP) to guarantee the purity, potency, and consistency of the API. Additionally, regulatory bodies such as the Food and Drug Administration (FDA) closely monitor the production and distribution of insulin APIs to maintain high standards of quality and patient safety.
In summary, insulin APIs are critical components in the management of diabetes. They are manufactured using advanced biotechnological methods and are utilized in the production of various insulin formulations. Rigorous quality control and regulatory compliance are essential to ensure the effectiveness and safety of insulin APIs for patients with diabetes.
Insulin Aspart (Insulin), classified under Anti-diabetics
Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.
Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.
Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.
These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.
It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.
In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.
Insulin Aspart manufacturers | traders | suppliers
We have 3 companies offering Insulin Aspart produced in 2 different countries.
Get in contact with the supplier of your choice:
- Nanjing Hanxin Pharmaceutical Technology Co.,Ltd. from China, product country of origin China
- Apino Pharma Co., Ltd. from China, product country of origin China
- Biocon from India, product country of origin India
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.
